Merck (MRK) Tops Q4 EPS by 9c; Guides FY23 EPS Below the Street

Merck (NYSE: MRK) reported Q4 EPS of $1.62, $0.09 better than the analyst estimate of $1.53. Revenue for the quarter came in at $13.8 billion versus the consensus estimate of $13.65 billion.

GUIDANCE:

Merck sees FY2023 EPS of $6.80-$6.95, versus the consensus of $7.36. Merck sees FY2023 revenue of $57.2-58.7 billion, versus the consensus of $58.07 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance